Bachem Holding AG: A Strong Start to 2025

In a remarkable display of resilience and strategic growth, Bachem Holding AG, a Swiss leader in the development and manufacture of peptides and oligonucleotides, has reported a robust financial performance in the first half of 2025. The company, headquartered in Bubendorf, has seen its stock soar by over 20% following the announcement of its impressive results, as reported by multiple financial news sources.

Financial Highlights

Bachem’s financial achievements in the first half of 2025 are noteworthy. The company reported a 30% increase in sales, reaching CHF 313.0 million, with an even more impressive 34% growth when adjusted for local currencies. This surge in sales is a testament to Bachem’s strong market position and its ability to meet the growing demands of the pharmaceutical and biotechnology sectors globally.

The company’s EBITDA also saw a significant increase, jumping 64% to CHF 91.0 million. This growth translated into an expanded margin of 29.1%, up from 23.1% in the previous year. Such financial health is indicative of Bachem’s efficient operations and its strategic investments in capacity expansion, which amounted to CHF 129.1 million during the first half of the year.

Strategic Growth and Future Outlook

Bachem’s growth is not just a result of increased sales but also strategic expansions and investments. The company has raised its 2025 sales growth guidance to 13-18%, reflecting its confidence in continued market demand and its ability to capitalize on it. A significant part of this growth strategy includes the expansion of its facilities, notably the new Building K facility and planned expansions in Sisslerfeld, aimed at bolstering its production capabilities.

Looking ahead, Bachem has set ambitious targets for 2026, aiming for annual sales exceeding CHF 1 billion and an EBITDA margin over 30%. These goals underscore the company’s commitment to not only sustaining its current growth trajectory but also expanding its footprint in the life sciences tools and services sector.

Conclusion

Bachem Holding AG’s strong performance in the first half of 2025 is a clear indicator of its robust business model, strategic investments, and the growing demand for its products in the global market. With a solid foundation and a clear vision for the future, Bachem is well-positioned to achieve its ambitious targets and continue its growth story in the coming years. As the company moves forward, it remains a key player in the health care sector, particularly in the life sciences tools and services industry, contributing significantly to advancements in pharmaceutical and biotechnology research and development.